NorthWest Biotherapeutics Inc (NWBO)

[Doktornolittle]

Many months ago I thought LP was quoted as saying that she did not want early results for the DCVax trial. That she wanted fully matured data.

If I remember that correctly; I want to point out that the advantage of full maturation may not just be increasing the odds of approval, it might increase the measured efficacy that would be used to determine reimbursement.

That is... I would think that when they measure efficacy for consideration of reimbursement they use the bottom of the shot-gun spread of possible underlying true efficacy. If so, narrowing that shot-gun spread by increasing the amount of data increases reimbursement.

So that a rolling review started early makes good sense, but an actual snapshot of efficacy for AA might be disadvantageous.